Abstract:Purpose: To investigate the radiolabeling of E-B5, a monoclonal antibody against Pro-GastrinReleasing Peptide(31-98)by Iodine and study the stability and immunoreactivity of I-E-B5. To determine the in vivo biodistribution of I-E-B5 in normal Kunming mouse and small cell lung cancerbearing nude mouse models(SCLC mouse model) to study the pharmacokinetics of the I-E-B5 in vivo. Characterize the radioimmunoimaging effect and the best imaging time of I-E-B5 in different types of tumors. Methods: I-E-B5 was labeled by chloramine–T method. The labeling efficiency and radiochemical purity were determined by thin-layer chromatography. The I-E-B5 was incubated at 37°C water bath by itself or mixed with normal human serum, the radiochemical purity was then checked at different time points to determine its stability, and the immunoreactivity was determined by cell binding assays.I-E-B5 was injected into the tail veins of the normal Kunming mice which were sacrificed at different time points after injection, and the blood and representative tissues were collected immediately, and the %ID/g (percentage injected dose per gram of tissue) and pharmacokinetic parameters were calculated at various time points. Similarly, T/NT (tumor to non-tumor radioacticity ratio) at various time points were calculated after injection of I-E-B5 into the SCLC model. Mouse models bearing small cell lung cancer, lung adenocarcinoma, colon cancer were utilized to study the radioimmunoimaging effect of I-E-B5, and calculate the T/B ratio (tumor volume to the corresponding location at the other side). Results: I-E-B5 labeling rate was 90.8%, radiochemical purity was 99.28%, and radioactivity was 2.69 MBq/ug. The radiochemical purity of I-E-B5 was 90% after 6 hr at 37°C water bath, and remained at more than 70% after 24 hrs. The radiochemical purity was over 68.1% after 24 hrs mixing with normal human serum. The immunobinding rate of I-E-B5 to NCI-H446 (SCLC cell lines) and A549 (lung adenocarcinoma cell lines) was 71.6%, and 33.2%, respectively. The pharmacokinetics of I-E-B5 is consistent with a two-compartment model with first-order absorption. It was primarily metabolized via liver and kidney. The serum clearance rate is relatively fast. The %ID/g of I-E-B5 in xenografts was dramatically increased to a level much higher than other tissues 48 hrs after injection, reached plateau at 72 hr, and the T/NT ratio was also gradually increased with time. Prominent uptake of I-E-B5 in xenografts of SCLC in nude mice was observed after 24 hrs of injection. The radioactivity in the xenografts was gradually increased with time, and reached the peak at 72 and 96 hr. Xenografts of colon cancer showed similar results as that of SCLC although at a lower level. No observable accumulation was seen in the xenografts of lung adenocarcinoma. The T/B ratio in xenografts of SCLC was consistently higher than in colon cancer at all the time points, and both were significantly higher than that of lung adenocarcinoma which remained stable during the observation duration. Conclusion: The labeling rate and radiochemical purity of I-E-B5 were high and stable both in vivo and vitro. The labeled E-B5 kept its immunologic activity. I-E-B5 selectively accumulated at tumors expressing proGRP, and could effectively target SCLC, therefore is a promising radioimmunoimaging reagent for SCLC.

Biodistribution of 131I-Anti-cea Monoclonal Antibody (C50) in Nude Mice Model and Patients of Colon Cancer

Biodistribution of 188Re-Anti-cea Monoclonal Antibody (C50) in BALB/C Mice Model of Colon Cancer

Radioimmunoimaging and Biodistribution of ~(131)I Labeled Anti-Cea Monoclonal Antibody C50 in Nude Mice Bearing Human Breast Carcinoma Xenografts

Radioimmumoimaging of 153Sm labeled anti-CEA monoclonal antibody in mude mice bearing human colon carcinoma

Radioimmunolocalization and blodistribution of 131Ⅰ labeled anti-CEA,TPS and mixture monoclonal antibody in nude mice bearing human breast cancer xenografts

Preliminary Application of 99Mtc-Labeled Anti-Cea Monoclonal Antibody Kit

Local Radioimmunotherapy of Breast Cancer-Bearing Nude Mice Using Anti-Cea Monoclonal Antibody C50 Labeled with 131I

Biokinetics of 131 I-labelled Monclonal Antibodies Against CEA in Ovarian Cancer Patients

The Biodistribution and Pretargeting Radioimmunoimaging of the Fusion Protein of Anti-Cea Single-Chain Antibody and Core-Streptavidin in Human Rectocolonic Tumor Bearing Nude Mice

Observation of Therapeutical Effect of ~(188)Re-Anti-cea Momoclonal Antibody on Mice Colon Cancer Model

Biodistribution of ~(131)I-D_2C_5 in nude mice bearing tumor

Studies of 99mTc labeled carcinoembyronic antigen monoclonal antibody C50 fragment Fab' and biodistrobution

[Influence of Combination of Low Dosage 131I-Labeled Anti-Carcinoembryonic Antigen Antibody C50 and 5-Fluorouracil on Tumor Growth of Colorectal Cancer Xenografts in Nude Mice].

Radioimmunotherapy of Human Colon Cancer Xenografts with<sup>131</sup>I-Labeled Anti-CEA Monoclonal Antibody

Induction of Tumor Cell Apoptosis in Colorectal Cancer Xenografts of Nude Mice with Low Dosage of ~(131) I-labelled Anti-Carcinoembryonic Antigen Antibody C50 Combined with Chemotherapy

Evaluation of the internal therapeutic effectiveness of 131I-antiEGFR-BSA-PCL in nude mice with colorectal cancer

Radioimmunotherapy of human colon cancer xenografts with 131I-labeled anti-CEA monoclonal antibody.

Radioimmunotherapy Of Human Colon Cancer Xenografts With I-131-Labeled Anti-Cea Monoclonal Antibody

Experimental Study of the Biological Property and Safety Limitation of 99Mtc-C50

Evaluation of Therapeutic Effectiveness Of131i-Antiegfr-bsa-pcl in a Mouse Model of Colorectal Cancer

Experimental study of pharmacokinetics and radioimmunoimaging of 131 Iodine-labeled monoclonal antibody E-B 5 against Pro-Gastrin-Releasing Peptide ( 31-98 )